menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Evaluating Landmark Clinical Data for HER2-low Breast Cancer

ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    A groundbreaking clinical study on patients with HER2-low breast cancer may impact they way we provide treatment. Dr. David Cameron from the University of Edinburgh in Scotland joins Dr. Pavanai Chalasani to share key results from the DESTINY Breast04 trial.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    A groundbreaking clinical study on patients with HER2-low breast cancer may impact they way we provide treatment. Dr. David Cameron from the University of Edinburgh in Scotland joins Dr. Pavanai Chalasani to share key results from the DESTINY Breast04 trial.

Facebook Comments

Schedule25 Sep 2022
Webpack App